| You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here. Prefer to view this content on our website? Click here.
Dear Fellow Investor,
In early November, we sent you trading ideas for flu season. In fact, we said, “As anyone with a respiratory system will tell you, flu season isn’t fun. As any investor holding pharmacy and flu-related, coughing-sniffling remedy stocks will tell you it’s one of the best times of the year.” “Just last year, the US CDC estimates there were 35 million to 65 million flu illnesses, 16 million to 30 million flu-related medical visits, 390,000 to 830,000 flu-related hospitalizations and 25,000 to 72,000 flu-related deaths. All of which we could easily see again this year,” we added. Today, we’re learning the 2025 flu season is the most intense it’s been in 15 years. According to the CDC, as noted by CNN, “So far this season, the CDC estimates, there have been at least 24 million flu illnesses, 310,000 hospitalizations and 13,000 deaths — including at least 57 children. Traditionally, flu season peaks around February. Overall, 43 states reported high or very high flu activity last week. Flu was most intense in the South, Southwest and western states.”
Keep reading for two of the top flu season stocks to buy right now. Huge Alerts With a $32.50 price target, see why Zack’s SCR says this tiny biotech firm is “worth watching.”
This stock is driving innovation in the wound care space and recently announced a significant patent. This is the first and only patent granted for use in tabular fenestrated allografts, which will support the company’s commercial efforts and expands its IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as it forges ahead in the market.
See why 2025 could be another breakout year of growth for this stock and its shareholders! Get the ticker here!
Company: Clorox (SYM: CLX)
It’s just one of the many reasons to consider dividend-paying stocks like Clorox (SYM: CLX). With a yield of 3.29%, oversold shares of CLX are a bargain at $148.36. Not only did it just catch strong support, but it’s also severely oversold and ready to bounce. From its last traded price of $2148.36, we’d like to see its refill its bearish gap around $160. Analysts at Barclays also raised its price target on CLX to $140 from $130. Analysts at Jefferies also raised their price target on CLX to $189 with a buy rating. In addition, recent CLX earnings weren’t too shabby. In its second quarter, the company’s EPS of $1.55 beat estimates by 15 cents. Revenue of $1.69 billion, while down 15.1% year over year, beat by $60 million. Moving forward, according to Seeking Alpha, “Clorox now expects to earn an adjusted profit of $6.95 to $7.35 from initial guidance of $6.65 to $6.90 per share with revenue expected to be down 1% to up 2%. Organic sales are expected to be up 4% to 7%.” Edge on the Street Next Door to Amazon's New AI Hub: A Hidden Investment Opportunity
Amazon just broke ground on a massive AI data center project in Canada. These facilities are critical to powering the next wave of AI innovation. But here's the real secret...A tiny, unknown company located just next door has the technology to supply the clean, uninterrupted power Amazon desperately needs for its expansion. [The full name and ticker symbol of the company is revealed here] Company: CVS Health (SYM: CVS) In November, we also highlighted opportunity in CVS Health (SYM: CVS), which traded at $53. It’s now at $63 and could also easily push higher with Clorox.
Last month, investment firm TD Cowen reiterated their buy rating for CVS with an $80 price target, matching J.P. Morgan's $80 price target from late last year. Other investment firms such as Jefferies and Barclays have been more conservative, but still maintain buy ratings with $69 and $71 price targets, respectively. Boxabl BOXABL Announces New $20,000 House
When the biggest names in your industry take an interest, you know you're onto something. That's the story with BOXABL. They've rethought housing by bringing assembly lines to new home construction. Not to mention, the company has gained the attention of investors like D.R. Horton. Where traditional homes take over 7 months to build, BOXABL factories can produce their signature Casita home in nearly four hours. Become an investor today. Have you been buying any seasonal stocks lately? Do you have your eye on any other flu season or cold weather stocks right now? Hit "reply" to this email and let us know! | 